Thesis
CYB003's dual Phase 3 PARADIGM program tests whether a deuterated psilocybin analog can deliver registrational MDD efficacy before the psychedelic field consolidates around a first mover
CYB003, a deuterated psilocybin analog with Breakthrough Therapy Designation, is running two concurrent Phase 3 trials targeting moderate-to-severe MDD across hundreds of patients. The thesis turns on whether the APPROACH trial delivers statistically significant MADRS reduction sufficient for NDA submission, with EMBRACE providing confirmatory depth. The primary threat is COMPASS Pathways' COMP360, which targets an overlapping depression population with the same serotonergic mechanism and is ahead in the regulatory queue.
Focus
CYB003 APPROACH Phase 3 topline data
Q4 2026
Bull
A positive MADRS or HAMD reduction meeting pre-specified endpoints across 220 participants would validate CYB003's deuterated psilocybin analog as registrationally viable, establishing a clear path to NDA submission and differentiating HELP from earlier-stage psychedelic competitors. Combined with the EMBRACE Phase 3 study, a win here would give HELP a two-study package consistent with FDA approval requirements and position it ahead of COMPASS's COMP360 program in the broader MDD indication.
Bear
The most likely failure modes are insufficient separation from placebo — a persistent challenge across psychedelic trials given the difficulty of blinding — or a treatment effect size that is statistically significant but too small to be clinically meaningful relative to approved antidepressants. A high placebo response rate across 45 U.S. sites, or unblinding driven by the subjective psychedelic experience, could erode the signal; safety signals requiring labeling restrictions would also undermine the commercial thesis even if efficacy thresholds are nominally met.
Unlock the full thesis for HELP.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.